Polymorphisms in NF-κB, PXR, LXR, PPARγ and risk of infammatory bowel disease

World Journal of Gastroenterology

Volumn 17, Issue 2, 2011, Pages 197-206

  Andersen, Vibeke ^a   Christensen, Jane ^b   Ernst, Anja ^c   Jacobsen, Bent A ^c   Tjønneland, Anne ^b   Krarup, Henrik B ^c   Vogel, Ulla ^d,e,f  

^a VIBORG HOSPITAL   (Denmark)

^b INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^e ROSKILDE UNIVERSITY   (Denmark)

^f NATIONAL RESEARCH CENTRE FOR THE WORKING ENVIRONMENT   (Denmark)

Author keywords

Crohn's disease; Genetic susceptibility; Single nucleotide polymorphisms; Smoking status; Transcription factors; Ulcerative colitis

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIVER X RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PREGNANE X RECEPTOR;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING HABIT; ULCERATIVE COLITIS;

EID: 79955756026     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i2.197     Document Type: Article

References (78)

1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of in-fammatory bowel disease. Nature 2007; 448: 427-434
2. Strober W, Fuss I, Mannon P. The fundamental basis of in-fammatory bowel disease. J Clin Invest 2007; 117: 514-521
3. Franke A, Balschun T, Karlsen TH, Hedderich J, May S, Lu T, Schuldt D, Nikolaus S, Rosenstiel P, Krawczak M, Schreiber S. Replication of signals from recent studies of Crohn's disease identifes previously unknown disease loci for ulcerative colitis. Nat Genet 2008; 40: 713-715
4. Østergaard M, Ernst A, Labouriau R, Dagiliené E, Krarup HB, Christensen M, Thorsgaard N, Jacobsen BA, Tage-Jensen U, Overvad K, Autrup H, Andersen V. Cyclooxygenase-2, multidrug resistance 1, and breast cancer resistance protein gene polymorphisms and infammatory bowel disease in the Danish population. Scand J Gastroenterol 2009; 44: 65-73
5. A Catalog of Published Genome-Wide Association Studies. 2008. Available from: URL: http://www.genome.gov/26525384
6. Andersen V, Ernst A, Christensen J, Østergaard M, Jacobsen BA, Tjønneland A, Krarup HB, Vogel U. The polymorphism rs3024505 proximal to IL-10 is associated with risk of ulcerative colitis and Crohns disease in a Danish case-control study. BMC Med Genet 2010; 11: 82
7. Ernst A, Andersen V, Østergaard M, Jacobsen BA, Dagiliene E, Pedersen IS, Drewes AM, Okkels H, Krarup HB. Genetic variants of glutathione S-transferases mu, theta, and pi display no susceptibility to infammatory bowel disease in the Danish population. Scand J Gastroenterol 2010; 45: 1068-1075
8. Törkvist L, Noble CL, Lördal M, Sjöqvist U, Lindforss U, Nimmo ER, Russell RK, Löfberg R, Satsangi J. Contribution of CARD15 variants in determining susceptibility to Crohn's disease in Sweden. Scand J Gastroenterol 2006; 41: 700-705
9. Medici V, Mascheretti S, Croucher PJ, Stoll M, Hampe J, Grebe J, Sturniolo GC, Solberg C, Jahnsen J, Moum B, Sch-reiber S, Vatn MH. Extreme heterogeneity in CARD15 and DLG5 Crohn disease-associated polymorphisms between German and Norwegian populations. Eur J Hum Genet 2006; 14: 459-468
10. Ernst A, Jacobsen B, Østergaard M, Okkels H, Andersen V, Dagiliene E, Pedersen IS, Thorsgaard N, Drewes AM, Krarup HB. Mutations in CARD15 and smoking confer susceptibility to Crohn's disease in the Danish population. Scand J Gastroen-terol 2007; 42: 1445-1451
11. Becker CE, O'Neill LA. Inflammasomes in inflammatory disorders: the role of TLRs and their interactions with NLRs. Semin Immunopathol 2007; 29: 239-248
12. Chen F, Castranova V, Shi X, Demers LM. New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 1999; 45: 7-17
13. Wang K, Wan YJ. Nuclear receptors and infammatory diseases. Exp Biol Med (Maywood) 2008; 233: 496-506
14. Bensinger SJ, Tontonoz P. Integration of metabolism and in-fammation by lipid-activated nuclear receptors. Nature 2008; 454: 470-477
15. Zhou C, Tabb MM, Nelson EL, Grün F, Verma S, Sadatrafei A, Lin M, Mallick S, Forman BM, Thummel KE, Blumberg B. Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabo lism and infammation. J Clin Invest 2006; 116: 2280-2289
16. di Masi A, De Marinis E, Ascenzi P, Marino M. Nuclear receptors CAR and PXR: Molecular, functional, and biomedical aspects. Mol Aspects Med 2009; 30: 297-343
17. Ahn KS, Aggarwal BB. Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann N Y Acad Sci 2005; 1056: 218-233
18. Greten FR, Arkan MC, Bollrath J, Hsu LC, Goode J, Miething C, Göktuna SI, Neuenhahn M, Fierer J, Paxian S, Van Rooijen N, Xu Y, O'Cain T, Jaffee BB, Busch DH, Duyster J, Schmid RM, Eckmann L, Karin M. NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell 2007; 130: 918-931
19. Steinbrecher KA, Harmel-Laws E, Sitcheran R, Baldwin AS. Loss of epithelial RelA results in deregulated intestinal pro-liferative/apoptotic homeostasis and susceptibility to infam-mation. J Immunol 2008; 180: 2588-2599
20. Nenci A, Becker C, Wullaert A, Gareus R, van Loo G, Danese S, Huth M, Nikolaev A, Neufert C, Madison B, Gumucio D, Neurath MF, Pasparakis M. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 2007; 446: 557-561
21. De Vry CG, Prasad S, Komuves L, Lorenzana C, Parham C, Le T, Adda S, Hoffman J, Kahoud N, Garlapati R, Shyam-sundar R, Mai K, Zhang J, Muchamuel T, Dajee M, Schryver B, McEvoy LM, Ehrhardt RO. Non-viral delivery of nuclear factor-kappaB decoy ameliorates murine infammatory bowel disease and restores tissue homeostasis. Gut 2007; 56: 524-533
22. Neurath MF, Pettersson S, Meyerzum Büschenfelde KH, Strober W. Local administration of antisense phosphorothio-ate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med 1996; 2: 998-1004
23. Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T, Knuechel R, Baeuerle PA, Schölmerich J, Gross V. Nuclear factor kappaB is activated in macrophages and epithelial cells of infamed intestinal mucosa. Gastroenterology 1998; 115: 357-369
24. Takedatsu H, Taylor KD, Mei L, McGovern DP, Landers CJ, Gonsky R, Cong Y, Vasiliauskas EA, Ippoliti A, Elson CO, Rotter JI, Targan SR. Linkage of Crohn's disease-related se-rological phenotypes: NFKB1 haplotypes are associated with anti-CBir1 and ASCA, and show reduced NF-kappaB activation. Gut 2009; 58: 60-67
25. Karban AS, Okazaki T, Panhuysen CI, Gallegos T, Potter JJ, Bailey-Wilson JE, Silverberg MS, Duerr RH, Cho JH, Gregers-en PK, Wu Y, Achkar JP, Dassopoulos T, Mezey E, Bayless TM, Nouvet FJ, Brant SR. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcer-ative colitis. Hum Mol Genet 2004; 13: 35-45
26. Borm ME, van Bodegraven AA, Mulder CJ, Kraal G, Bouma G. A NFKB1 promoter polymorphism is involved in susceptibility to ulcerative colitis. Int J Immunogenet 2005; 32: 401-405
27. Glas J, Török HP, Tonenchi L, Müller-Myhsok B, Mussack T, Wetzke M, Klein W, Epplen JT, Griga T, Schiemann U, Lohse P, Seiderer J, Schnitzler F, Brand S, Ochsenkühn T, Folwac-zny M, Folwaczny C. Role of the NFKB1 -94ins/delATTG promoter polymorphism in IBD and potential interactions with polymorphisms in the CARD15/NOD2, IKBL, and IL-1RN genes. Infamm Bowel Dis 2006; 12: 606-611
28. De Jager PL, Franchimont D, Waliszewska A, Bitton A, Cohen A, Langelier D, Belaiche J, Vermeire S, Farwell L, Goris A, Libioulle C, Jani N, Dassopoulos T, Bromfeld GP, Dubois B, Cho JH, Brant SR, Duerr RH, Yang H, Rotter JI, Silverberg MS, Steinhart AH, Daly MJ, Podolsky DK, Louis E, Hafler DA, Rioux JD. The role of the Toll receptor pathway in sus ceptibility to inflammatory bowel diseases. Genes Immun 2007; 8: 387-397
29. Latiano A, Palmieri O, Valvano MR, Bossa F, Latiano T, Cor-ritore G, DeSanto E, Andriulli A, Annese V. Evaluating the role of the genetic variations of PTPN22, NFKB1, and FcGRII-IA genes in inflammatory bowel disease: a meta-analysis. Infamm Bowel Dis 2007; 13: 1212-1219
30. Oliver J, Gómez-García M, Paco L, López-Nevot MA, Piñero A, Correro F, Martín L, Brieva JA, Nieto A, Martín J. A functional polymorphism of the NFKB1 promoter is not associated with ulcerative colitis in a Spanish population. Infamm Bowel Dis 2005; 11: 576-579
31. Mirza MM, Fisher SA, Onnie C, Lewis CM, Mathew CG, Sanderson J, Forbes A. No association of the NFKB1 promoter polymorphism with ulcerative colitis in a British case control cohort. Gut 2005; 54: 1205-1206
32. Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and infammatory signaling. J Clin Invest 2006; 116: 607-614
33. Hong C, Tontonoz P. Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors. Curr Opin Genet Dev 2008; 18: 461-467
34. Ghisletti S, Huang W, Ogawa S, Pascual G, Lin ME, Willson TM, Rosenfeld MG, Glass CK. Parallel SUMOylation-depen-dent pathways mediate gene- and signal-specifc transrepres-sion by LXRs and PPARgamma. Mol Cell 2007; 25: 57-70
35. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, Rose DW, Willson TM, Rosenfeld MG, Glass CK. A SU-MOylation-dependent pathway mediates transrepression of infammatory response genes by PPAR-gamma. Nature 2005; 437: 759-763
36. Yamamoto K, Ninomiya Y, Iseki M, Nakachi Y, Kanesaki-Yatsuka Y, Yamanoue Y, Itoh T, Nishii Y, Petrovsky N, Oka-zaki Y. 4-Hydroxydocosahexaenoic acid, a potent peroxisome proliferator-activated receptor gamma agonist alleviates the symptoms of DSS-induced colitis. Biochem Biophys Res Com-mun 2008; 367: 566-572
37. Sugawara K, Olson TS, Moskaluk CA, Stevens BK, Hoang S, Kozaiwa K, Cominelli F, Ley KF, McDuffie M. Linkage to peroxisome proliferator-activated receptor-gamma in SAMP1/YitFc mice and in human Crohn's disease. Gastroen-terology 2005; 128: 351-360
38. Ramakers JD, Verstege MI, Thuijls G, Te Velde AA, Mensink RP, Plat J. The PPARgamma agonist rosiglitazone impairs colonic infammation in mice with experimental colitis. J Clin Immunol 2007; 27: 275-283
39. Dubuquoy L, Jansson EA, Deeb S, Rakotobe S, Karoui M, Colombel JF, Auwerx J, Pettersson S, Desreumaux P. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology 2003; 124: 1265-1276
40. Doney A, Fischer B, Frew D, Cumming A, Flavell DM, World M, Montgomery HE, Boyle D, Morris A, Palmer CN. Haplo-type analysis of the PPARgamma Pro12Ala and C1431T variants reveals opposing associations with body weight. BMC Genet 2002; 3: 21
41. Masugi J, Tamori Y, Mori H, Koike T, Kasuga M. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun 2000; 268: 178-182
42. Shrestha UK, Karimi O, Crusius JB, Zhou F, Wang Z, Chen Z, van Bodegraven AA, Xiao J, Morré SA, Wang H, Li J, Xia B. Distribution of peroxisome proliferator-activated receptor-gamma polymorphisms in Chinese and Dutch patients with inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 312-319
43. Wang F, Tahara T, Arisawa T, Sakata M, Takahama K, Wata-nabe M, Hirata I, Nakano H. Polymorphism of peroxisome proliferator-activated receptor gamma is not associated to Japanese ulcerative colitis. Hepatogastroenterology 2008; 55: 73-75
44. Leung E, Hong J, Fraser AG, Merriman TR, Vishnu P, Kris-sansen GW. Peroxisome proliferator-activated receptor-gamma gene polymorphisms and Crohn's disease. Int J Colorectal Dis 2007; 22: 453-454
45. Langmann T, Moehle C, Mauerer R, Scharl M, Liebisch G, Zahn A, Stremmel W, Schmitz G. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology 2004; 127: 26-40
46. Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, Daly A, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Wrighton SA, Hancock M, Kim RB, Strom S, Thummel K, Russell CG, Hudson JR Jr, Schuetz EG, Boguski MS. The human pregnane X receptor: genomic structure and identifca-tion and functional characterization of natural allelic variants. Pharmacogenetics 2001; 11: 555-572
47. Dring MM, Goulding CA, Trimble VI, Keegan D, Ryan AW, Brophy KM, Smyth CM, Keeling PW, O'Donoghue D, O'Sullivan M, O'Morain C, Mahmud N, Wikström AC, Kelleher D, McManus R. The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology 2006; 130: 341-348; quiz 592
48. Amre DK, Mack DR, Israel D, Morgan K, Krupoves A, Costea I, Lambrette P, Grimard G, Deslandres C, Levy E, Seidman EG. Investigation of associations between the pregnane-X receptor gene (NR1I2) and Crohn's disease in Canadian children using a gene-wide haplotype-based approach. Infamm Bowel Dis 2008; 14: 1214-1218
49. Ho GT, Soranzo N, Tate SK, Drummond H, Nimmo ER, Tenesa A, Arnott ID, Satsangi J. Lack of association of the pregnane X receptor (PXR/NR1I2) gene with infammatory bowel disease: parallel allelic association study and gene wide haplotype analysis. Gut 2006; 55: 1676-1677
50. Martínez A, Márquez A, Mendoza J, Taxonera C, Fernández-Arquero M, Díaz-Rubio M, de la Concha EG, Urcelay E. Role of the PXR gene locus in inflammatory bowel diseases. In-famm Bowel Dis 2007; 13: 1484-1487
51. Adighibe O, Arepalli S, Duckworth J, Hardy J, Wavrant-DeVrièze F. Genetic variability at the LXR gene (NR1H2) may contribute to the risk of Alzheimer's disease. Neurobiol Aging 2006; 27: 1431-1434
52. Rodríguez-Rodríguez E, Llorca J, Mateo I, Infante J, Sánchez-Quintana C, García-Gorostiaga I, Fernández-Viadero C, Peña N, Berciano J, Combarros O. No association of genetic variants of liver X receptor-beta with Alzheimer's disease risk.Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 650-653
53. Infante J, Rodríguez-Rodríguez E, Mateo I, Llorca J, Vázquez-Higuera JL, Berciano J, Combarros O. Gene-gene interaction between heme oxygenase-1 and liver X receptor-beta and Alzheimer's disease risk. Neurobiol Aging 2010; 31: 710-714
54. Hermann M, Krum H, Ruschitzka F. To the heart of the matter: coxibs, smoking, and cardiovascular risk. Circulation 2005; 112: 941-945
55. Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S. Smoking and infammatory bowel disease: a meta-analysis. Mayo Clin Proc 2006; 81: 1462-1471
56. Aldhous MC, Prescott RJ, Roberts S, Samuel K, Waterfall M, Satsangi J. Does nicotine influence cytokine profile and subsequent cell cycling/apoptotic responses in infammatory bowel disease? Infamm Bowel Dis 2008; 14: 1469-1482
57. Mishra NC, Rir-Sima-Ah J, Langley RJ, Singh SP, Peña-Philippides JC, Koga T, Razani-Boroujerdi S, Hutt J, Campen M, Kim KC, Tesfaigzi Y, Sopori ML. Nicotine primarily suppresses lung Th2 but not goblet cell and muscle cell responses to allergens. J Immunol 2008; 180: 7655-7663
58. Mian MF, Stämpfi MR, Mossman KL, Ashkar AA. Cigarette smoke attenuation of poly I:C-induced innate antiviral responses in human PBMC is mainly due to inhibition of IFN-beta production. Mol Immunol 2009; 46: 821-829
59. Vangsted AJ, Klausen TW, Ruminski W, Gimsing P, Andersen NF, Gang AO, Abildgaard N, Knudsen LM, Nielsen JL, Gregersen H, Vogel U. The polymorphism IL-1beta T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT. Bone Marrow Transplant 2009; 43: 539-545
60. Vogel U, Christensen J, Nexø BA, Wallin H, Friis S, Tjøn-neland A. Peroxisome proliferator-activated [corrected] re-ceptor-gamma2 [corrected] Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. Carcinogenesis 2007; 28: 427-434
61. Vogel U, Christensen J, Dybdahl M, Friis S, Hansen RD, Wal-lin H, Nexø BA, Raaschou-Nielsen O, Andersen PS, Overvad K, Tjønneland A. Prospective study of interaction between alcohol, NSAID use and polymorphisms in genes involved in the infammatory response in relation to risk of colorectal cancer. Mutat Res 2007; 624: 88-100
62. Greenland S. Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology 1995; 6: 356-365
63. Vogel U, Christensen J, Wallin H, Friis S, Nexø BA, Tjøn-neland A. Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes. Mutat Res 2007; 617: 138-146
64. Genetic Power Calculator. 2009. Available from: URL: http://pngu.mgh.harvard.edu/~purcell/gpc/cc2.html
65. Daly AK. Candidate gene case-control studies. Pharmacoge-nomics 2003; 4: 127-139
66. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med 2002; 4: 45-61
67. Statistics Denmark. 2009. Available from: URL: http://www.dst.dk/HomeUK/Statistics/Key_indicators/Population/pop_quarterly.aspx
68. Fowler EV, Doecke J, Simms LA, Zhao ZZ, Webb PM, Hay-ward NK, Whiteman DC, Florin TH, Montgomery GW, Cavanaugh JA, Radford-Smith GL. ATG16L1 T300A shows strong associations with disease subgroups in a large Australian IBD population: further support for significant disease heterogeneity. Am J Gastroenterol 2008; 103: 2519-2526
69. Achkar JP, Dassopoulos T, Silverberg MS, Tuvlin JA, Duerr RH, Brant SR, Siminovitch K, Reddy D, Datta LW, Bayless TM, Zhang L, Barmada MM, Rioux JD, Steinhart AH, McLeod RS, Griffiths AM, Cohen Z, Yang H, Bromfield GP, Schumm P, Hanauer SB, Cho JH, Nicolae DL. Phenotype-stratifed genetic linkage study demonstrates that IBD2 is an extensive ulcer-ative colitis locus. Am J Gastroenterol 2006; 101: 572-580
70. Shah YM, Ma X, Morimura K, Kim I, Gonzalez FJ. Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-kappaB target gene expression. Am J Physiol Gastrointest Liver Physiol 2007; 292: G1114-G1122
71. Wahli W. A gut feeling of the PXR, PPAR and NF-kappaB connection. J Intern Med 2008; 263: 613-619
72. Panwala CM, Jones JC, Viney JL. A novel model of infam-matory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 1998; 161: 5733-5744
73. Langmann T, Schmitz G. Loss of detoxifcation in infamma-tory bowel disease. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 358-359
74. Annese V, Valvano MR, Palmieri O, Latiano A, Bossa F, Andriulli A. Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis. World J Gastroenterol 2006; 12: 3636-3644
75. Thornton SJ, Wong E, Lee SD, Wasan KM. Effect of dietary fat on hepatic liver X receptor expression in P-glycoprotein defcient mice: implications for cholesterol metabolism. Lipids Health Dis 2008; 7: 21
76. Chisaki I, Kobayashi M, Itagaki S, Hirano T, Iseki K. Liver X receptor regulates expression of MRP2 but not that of MDR1 and BCRP in the liver. Biochim Biophys Acta 2009; 1788: 2396-2403
77. Jones DT, Osterman MT, Bewtra M, Lewis JD. Passive smoking and infammatory bowel disease: a meta-analysis. Am J Gastroenterol 2008; 103: 2382-2393
78. Lashner BA, Shaheen NJ, Hanauer SB, Kirschner BS. Passive smoking is associated with an increased risk of developing inflammatory bowel disease in children. Am J Gastroenterol 1993; 88: 356-359